{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:27:27Z","timestamp":1786980447289,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"crossref","award":["EMR\/2016\/003365"],"award-info":[{"award-number":["EMR\/2016\/003365"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Central Institute of Industrial research (CSIR), New Delhi, India","award":["8948A\/17"],"award-info":[{"award-number":["8948A\/17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Brain Tumor Pathol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10014-019-00350-1","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T02:06:35Z","timestamp":1565057195000},"page":"152-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade?"],"prefix":"10.1007","volume":"36","author":[{"given":"Aruna","family":"Nambirajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prit Benny","family":"Malgulwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agrima","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher Thej","family":"Boorgula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Doddamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmohan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-3296","authenticated-orcid":false,"given":"Mehar Chand","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"key":"350_CR1","first-page":"106","volume-title":"WHO classification of tumours of the central nervous system","author":"DW Ellison","year":"2016","unstructured":"Ellison DW, McLendon R, Wiestler OD et al (2016) Ependymoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC, Lyon, pp 106\u2013112","edition":"4"},{"key":"350_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-016-1643-0","volume":"133","author":"KW Pajtler","year":"2017","unstructured":"Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A et al (2017) The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 133:5\u201312","journal-title":"Acta Neuropathol"},{"key":"350_CR3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","volume":"27","author":"KW Pajtler","year":"2015","unstructured":"Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F et al (2015) Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27:728\u2013743","journal-title":"Cancer Cell"},{"key":"350_CR4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature13109","volume":"506","author":"M Parker","year":"2014","unstructured":"Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y et al (2014) C11orf95\u2013RELA fusions drive oncogenic NF-\u03baB signalling in ependymoma. Nature 506:451\u2013455","journal-title":"Nature"},{"key":"350_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature13108","volume":"506","author":"SC Mack","year":"2014","unstructured":"Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, St\u00fctz AM et al (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506:445\u2013450","journal-title":"Nature"},{"key":"350_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11060-018-2767-y","volume":"138","author":"PB Malgulwar","year":"2018","unstructured":"Malgulwar PB, Nambirajan A, Pathak P, Faruq M, Rajeshwari M, Singh M et al (2018) C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin. J Neurooncol 138:29\u201339","journal-title":"J Neurooncol"},{"key":"350_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/PAS.0000000000000979","volume":"43","author":"M Gessi","year":"2019","unstructured":"Gessi M, Giagnacovo M, Modena P, Elefante G, Gianno F, Buttarelli FR et al (2019) Role of immunohistochemistry in the identification of supratentorial C11ORF95-RELA fused ependymoma in routine neuropathology. Am J Surg Pathol 43:56\u201363","journal-title":"Am J Surg Pathol"},{"key":"350_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00401-017-1752-4","volume":"134","author":"P Panwalkar","year":"2017","unstructured":"Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C et al (2017) Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 134:705\u2013714","journal-title":"Acta Neuropathol"},{"key":"350_CR9","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"350_CR10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nrneurol.2015.139","volume":"11","author":"M Preusser","year":"2015","unstructured":"Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH (2015) Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 11:504\u2013514","journal-title":"Nat Rev Neurol."},{"key":"350_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jneuroim.2014.10.008","volume":"277","author":"LY Kong","year":"2014","unstructured":"Kong LY, Wei J, Haider AS, Liebelt BD, Ling X, Conrad CA et al (2014) Therapeutic targets in subependymoma. J Neuroimmunol 277:168\u2013175","journal-title":"J Neuroimmunol"},{"key":"350_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5414\/NP300988","volume":"36","author":"B Dumont","year":"2017","unstructured":"Dumont B, Forest F, Dal Col P, Karpathiou G, Stephan JL, Vassal F et al (2017) PD1 and PD-L1 in ependymoma might not be therapeutic targets. Clin Neuropathol 36:90\u201392","journal-title":"Clin Neuropathol"},{"key":"350_CR13","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/neuonc\/now132","volume":"18","author":"ST Garber","year":"2016","unstructured":"Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG et al (2016) Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 18:1357\u20131366","journal-title":"Neuro Oncol"},{"key":"350_CR14","doi-asserted-by":"publisher","first-page":"e26960","DOI":"10.1002\/pbc.26960","volume":"65","author":"DA Witt","year":"2018","unstructured":"Witt DA, Donson AM, Amani V, Moreira DC, Sanford B, Hoffman LM et al (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: implications for PD-1-targeted therapy. Pediatr Blood Cancer 65:e26960","journal-title":"Pediatr Blood Cancer"},{"key":"350_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-018-2886-5","volume":"139","author":"K Hwang","year":"2018","unstructured":"Hwang K, Koh EJ, Choi EJ, Kang TH, Han JH, Choe G et al (2018) PD-1\/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population. J Neurooncol 139:281\u2013291","journal-title":"J Neurooncol"},{"key":"350_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00262-018-2278-x","volume":"68","author":"SJ Nam","year":"2019","unstructured":"Nam SJ, Kim YH, Park JE, Ra YS, Khang SK, Cho YH et al (2019) Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma. Cancer Immunol Immunother 68:305\u2013318","journal-title":"Cancer Immunol Immunother"},{"key":"350_CR17","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","volume":"35","author":"R B\u00fcttner","year":"2017","unstructured":"B\u00fcttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ et al (2017) Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol 35:3867\u20133876","journal-title":"J Clin Oncol"},{"key":"350_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.7150\/jca.21842","volume":"9","author":"S Cui","year":"2018","unstructured":"Cui S, Dong L, Qian J, Ye L, Jiang L (2018) Classifying non-small cell lung cancer by status of programmed cell death ligand 1 and tumor-infiltrating lymphocytes on tumor cells. J Cancer 9:129\u2013134","journal-title":"J Cancer"},{"key":"350_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","volume":"100","author":"S Gandini","year":"2016","unstructured":"Gandini S, Massi D, Mandal\u00e0 M (2016) PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol 100:88\u201398","journal-title":"Crit Rev Oncol Hematol"},{"key":"350_CR20","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1200\/JCO.2018.36.15_suppl.2008","volume":"36","author":"JFD Groot","year":"2018","unstructured":"Groot JFD, Penas-Prado M, Mandel JJ, O\u2019Brien BJ, Weathers SPS, Zhou S et al (2018) Window of opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. J Clin Oncol 36:2008. \n                    https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.2008","journal-title":"J Clin Oncol"},{"key":"350_CR21","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT et al (2013) Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5:200ra116","journal-title":"Sci Transl Med"},{"key":"350_CR22","doi-asserted-by":"publisher","first-page":"34221","DOI":"10.18632\/oncotarget.5950","volume":"6","author":"LF Campesato","year":"2015","unstructured":"Campesato LF, Barroso-Sousa R, Jimenez L, Correa BR, Sabbaga J, Hoff PM et al (2015) Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget 6:34221\u201334227","journal-title":"Oncotarget"},{"key":"350_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jtho.2018.11.006","volume":"14","author":"M Carbone","year":"2019","unstructured":"Carbone M, Yang H, Gaudino G (2019) Does chromothripsis make mesothelioma an immunogenic cancer? J Thorac Oncol 14:157\u2013159","journal-title":"J Thorac Oncol"},{"key":"350_CR24","doi-asserted-by":"publisher","first-page":"30093","DOI":"10.1038\/srep30093","volume":"6","author":"P Koirala","year":"2016","unstructured":"Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS et al (2016) Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep 6:30093","journal-title":"Sci Rep"},{"key":"350_CR25","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1097\/MPH.0000000000001339","volume":"41","author":"HS Gorsi","year":"2019","unstructured":"Gorsi HS, Malicki DM, Barsan V, Tumblin M, Yeh-Nayre L, Milburn M et al (2019) Nivolumab in the treatment of recurrent or refractory pediatric brain tumors: a single institutional experience. J Pediatr Hematol Oncol 41:e235\u2013e241","journal-title":"J Pediatr Hematol Oncol"},{"key":"350_CR26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","volume":"14","author":"AS Mansfield","year":"2019","unstructured":"Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L et al (2019) Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J Thorac Oncol 14:276\u2013287","journal-title":"J Thorac Oncol"},{"key":"350_CR27","doi-asserted-by":"publisher","first-page":"e0123410","DOI":"10.1371\/journal.pone.0123410","volume":"10","author":"K Gowrishankar","year":"2015","unstructured":"Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P (2015) Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-\u03baB. PLoS One 10:e0123410","journal-title":"PLoS One"},{"key":"350_CR28","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","volume":"5","author":"W Fang","year":"2014","unstructured":"Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T et al (2014) EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget 5:12189\u201312202","journal-title":"Oncotarget"},{"key":"350_CR29","doi-asserted-by":"publisher","first-page":"e1423170","DOI":"10.1080\/2162402X.2017.1423170","volume":"7","author":"A Asgarova","year":"2018","unstructured":"Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M et al (2018) PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology 7:e1423170","journal-title":"Oncoimmunology"},{"key":"350_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.humpath.2018.07.018","volume":"82","author":"PB Malgulwar","year":"2018","unstructured":"Malgulwar PB, Nambirajan A, Pathak P, Rajeshwari M, Suri V, Sarkar C et al (2018) Epithelial-to-mesenchymal transition\u2013related transcription factors are up-regulated in ependymomas and correlate with a poor prognosis. Hum Pathol 82:149\u2013157","journal-title":"Hum Pathol"},{"key":"350_CR31","doi-asserted-by":"publisher","first-page":"7428","DOI":"10.4049\/jimmunol.0902811","volume":"183","author":"AM Donson","year":"2009","unstructured":"Donson AM, Birks DK, Barton VN, Wei Q, Kleinschmidt-Demasters BK, Handler MH et al (2009) Immune gene and cell enrichment is associated with a good prognosis in ependymoma. J Immunol 183:7428\u20137440","journal-title":"J Immunol"},{"key":"350_CR32","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00401-013-1212-8","volume":"127","author":"LM Hoffman","year":"2014","unstructured":"Hoffman LM, Donson AM, Nakachi I, Griesinger AM, Birks DK, Amani V et al (2014) Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol 127:731\u2013745","journal-title":"Acta Neuropathol"},{"key":"350_CR33","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1158\/2326-6066.CIR-15-0061","volume":"3","author":"AM Griesinger","year":"2015","unstructured":"Griesinger AM, Josephson RJ, Donson AM, Mulcahy Levy JM, Amani V, Birks DK et al (2015) Interleukin-6\/STAT3 pathway signaling drives an inflammatory phenotype in Group A ependymoma. Cancer Immunol Res 3:1165\u20131174","journal-title":"Cancer Immunol Res"},{"key":"350_CR34","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.4049\/jimmunol.1301966","volume":"191","author":"AM Griesinger","year":"2013","unstructured":"Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A et al (2013) Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol 191:4880\u20134888","journal-title":"J Immunol"},{"key":"350_CR35","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1038\/s41598-017-04023-x","volume":"7","author":"S Xue","year":"2017","unstructured":"Xue S, Song G, Yu J (2017) The prognostic significance of PD-L1 expression in patients with glioma: a meta-analysis. Sci Rep 7:4231","journal-title":"Sci Rep"},{"key":"350_CR36","first-page":"4180517","volume":"2018","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhu C, Song W, Li J, Zhao G, Cao H (2018) PD-L1 expression and CD8(+) T cell infiltration predict a favorable prognosis in advanced gastric cancer. J Immunol Res 2018:4180517","journal-title":"J Immunol Res"}],"container-title":["Brain Tumor Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-019-00350-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10014-019-00350-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-019-00350-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T19:30:23Z","timestamp":1596569423000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10014-019-00350-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1007\/s10014-019-00350-1","relation":{},"ISSN":["1433-7398","1861-387X"],"issn-type":[{"value":"1433-7398","type":"print"},{"value":"1861-387X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,6]]},"assertion":[{"value":"21 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research has been ethically approved by the institute ethics committee (Ref. No. IEC-602\/03.11.2017)","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}